Sanofi’s Board of Directors will propose the appointment of Christel Heydemann as an Independent Director at its Annual General Meeting (AGM) on 29^th April, 2026, along with the renewal of the mandates of Christophe Babule and Jean-Paul Kress.

Patrick Kron, Independent Director and Chairman of the Nomination, Governance and CSR Committee, will step down from the Board at the end of his term, which will expire at the upcoming AGM on 29^th April. The Board thanks Patrick Kron for his decisive contribution to its work over the past 12 years, particularly with respect to key governance decisions.

Christel Heydemann has been Chief Executive Officer (CEO) of the Orange Group since April 2022, after serving as a member of the Board of Directors from July 2017. She began her career at Alcatel in 1999, where she held various management positions, including during the merger between Alcatel and Lucent.

In 2008, she was appointed Chief Commercial Officer for France and joined the Executive Committee of Alcatel-Lucent France. In 2011, she headed up Human Resources and Transformation for the group. In 2014, she joined Schneider Electric.

In 2017, she was appointed Chairman and CEO of Schneider Electric France. In 2021, she took on the role of Executive Vice President, Europe Operations. A graduate of École Polytechnique and École Nationale des Ponts et Chaussées, Christel Heydemann is actively committed to promote diversity and innovation, particularly in encouraging women to pursue careers in science and technology. She is an Officer of the French National Order of Merit and a Knight of the French Legion of Honour. 

“We sincerely thank Patrick Kron for the commitment and rigour he has brought to the Board’s work over the past 12 years, both as a Director and in the various committee chair roles he has held. The proposed appointment of Christel Heydemann reflects the Board’s determination to further strengthen the diversity of expertise and backgrounds within our governance. Her recognised experience leading major international groups, her expertise in industrial and digital transformation and her strategic vision will be valuable assets in supporting Sanofi through the next phase of its development,” said Frédéric Oudéa, Chairman –Board of Directors, Sanofi.

With these appointments and the arrival of Belén Garijo as CEO and Director, the Board would remain composed of 16 members, including two employee representatives, gender parity (57 per cent of women excluding employee representatives). 

The composition of the Board’s specialised committees will be reviewed following the AGM scheduled for 29^th April, 2026.